Skip to main content Accessibility help

Vitamin E–drug interactions: molecular basis and clinical relevance

  • Maren Podszun (a1) and Jan Frank (a1)


Vitamin E (α-, β-, γ- and δ-tocopherol and -tocotrienol) is an essential factor in the human diet and regularly taken as a dietary supplement by many people, who act under the assumption that it may be good for their health and can do no harm. With the publication of meta-analyses reporting increased mortality in persons taking vitamin E supplements, the safety of the micronutrient was questioned and interactions with prescription drugs were suggested as one potentially underlying mechanism. Here, we review the evidence in the scientific literature for adverse vitamin E–drug interactions and discuss the potential of each of the eight vitamin E congeners to alter the activity of drugs. In summary, there is no evidence from animal models or randomised controlled human trials to suggest that the intake of tocopherols and tocotrienols at nutritionally relevant doses may cause adverse nutrient–drug interactions. Consumption of high-dose vitamin E supplements ( ≥  300 mg/d), however, may lead to interactions with the drugs aspirin, warfarin, tamoxifen and cyclosporine A that may alter their activities. For the majority of drugs, however, interactions with vitamin E, even at high doses, have not been observed and are thus unlikely.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Vitamin E–drug interactions: molecular basis and clinical relevance
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Vitamin E–drug interactions: molecular basis and clinical relevance
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Vitamin E–drug interactions: molecular basis and clinical relevance
      Available formats


Corresponding author

* Corresponding author: Professor Jan Frank, fax +49 711 459 23386, email


Hide All
1 Hathcock, JN, Azzi, A, Blumberg, J, et al. (2005) Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr 81, 736745.
2 Miller, ERIII, Pastor-Barriuso, R, Dalal, D, et al. (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142, 3746.
3 Bjelakovic, G, Nikolova, D, Gluud, LL, et al. (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297, 842857.
4 Brigelius-Flohe, R (2003) Vitamin E and drug metabolism. Biochem Biophys Res Commun 305, 737740.
5 Frank, J, Chin, XWD, Schrader, C, et al. (2012) Do tocotrienols have potential as neuroprotective dietary factors? Ageing Res Rev 11, 163180.
6 Kamal-Eldin, A & Appelqvist, LA (1996) The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids 31, 671701.
7 Evans, HM & Bishop, KS (1922) On the existence of a hitherto unrecognized dietary factor essential for reproduction. Science 56, 650651.
8 Leth, T & Sondergaard, H (1977) Biological activity of vitamin E compounds and natural materials by the resorption-gestation test, and chemical determination of the vitamin E activity in foods and feeds. J Nutr 107, 22362243.
9 Burton, GW, Joyce, A & Ingold, KU (1982) First proof that vitamin E is major lipid-soluble, chain-breaking antioxidant in human blood plasma. Lancet ii, 327.
10 Azzi, A, Gysin, R, Kempna, P, et al. (2004) Vitamin E mediates cell signaling and regulation of gene expression. Ann N Y Acad Sci 1031, 8695.
11 Rimbach, G, Minihane, AM, Majewicz, J, et al. (2002) Regulation of cell signalling by vitamin E. Proc Nutr Soc 61, 415425.
12 Frank, J, de Pascual Teresa, S & Rimbach, G (2006) Nutrigenomics – new frontiers in antioxidant research. Food Sci Technol Bull: Functional Foods 3, 112.
13 Grebenstein, N, Schumacher, M, Graeve, L, et al. (2014) α-Tocopherol transfer protein is not required for the discrimination against γ-tocopherol in vivo but protects it from side-chain degradation in vitro . Mol Nutr Food Res 58, 10521060.
14 Institute of Medicine (2000) Vitamin E. In Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids, pp. 186283. Washington, DC: The National Academies Press.
15 Bundesministerium für Ernährung, Landwirtschaft und Verbraucherschutz (Federal Ministry of Food, Agriculture and Consumer Protection) (2008) Ergebnisbericht, Teil 2; Nationale Verzehrsstudie II (Results Report, Part 2; National Nutrition Survey II) (accessed July 2014).
16 Schwab, S, Heier, M, Schneider, A, et al. (2014) The use of dietary supplements among older persons in Southern Germany – results from the KORA-age study. J Nutr Health Aging 18, 510519.
17 Balluz, LS, Kieszak, SM, Philen, RM, et al. (2000) Vitamin and mineral supplement use in the United States. Results from the third National Health and Nutrition Examination Survey. Arch Fam Med 9, 258262.
18 Wolfram, G (2003) New reference values for nutrient intake in Germany, Austria and Switzerland (DACH-Reference Values). Forum Nutr 56, 9597.
19 Deutsche Gesellschaft für Ernährung e.V. (DGE), Österreichische Gesellschaft für Ernährung (ÖGE) & Schweizerische Gesellschaft für Ernährungsforschung (SGE) (2013) Referenzwerte Für Die Nährstoffzufuhr. 1. Auflage ed. (Dietary Reference Values. 1st edition). Neustadt an der Weinstraße: Umschau Buchverlag.
20 Bell, SJ & Grochoski, GT (2008) How safe is vitamin E supplementation? Crit Rev Food Sci Nutr 48, 760774.
21 Frank, J & Rimbach, G (2009) Vitamin E in disease prevention - a critical appraisal of vitamin E supplementation trials. Aktuel Ernaehr Med 34, 131140.
22 Brigelius-Flohe, R (2007) Adverse effects of vitamin E by induction of drug metabolism. Genes Nutr 2, 249256.
23 Benet, L (1984) Pharmacokinetics: basic principles and its use as a tool in drug metabolism. In Drug Metabolism and Drug Toxicity, pp. 199211 [Mitchell, R and Horning, M, editors]. New York: Raven Press.
24 Chan, LN (2002) Drug-nutrient interaction in clinical nutrition. Curr Opin Clin Nutr Metab Care 5, 327332.
25 Buettner, GR (1993) The pecking order of free radicals and antioxidants: lipid peroxidation, α-tocopherol, and ascorbate. Arch Biochem Biophys 300, 535543.
26 Roninson, IB, Chin, JE, Choi, KG, et al. (1986) Isolation of human MDR DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A 83, 45384542.
27 Thiebaut, F, Tsuruo, T, Hamada, H, et al. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84, 77357738.
28 Mayer, U, Wagenaar, E, Beijnen, JH, et al. (1996) Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 119, 10381044.
29 Dürr, D, Stieger, B, Kullak-Ublick, GA, et al. (2000) St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68, 598604.
30 Zhou, C, Tabb, MM, Sadatrafiei, A, et al. (2004) Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos 32, 10751082.
31 Abuznait, AH, Qosa, H, O'Connell, ND, et al. (2011) Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products. Food Chem Toxicol 49, 27652772.
32 Kaminsky, LS & Zhang, Q (2003) The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 31, 15201525.
33 Guengerich, FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39, 117.
34 Benet, LZ & Cummins, CL (2001) The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 50, S3S11.
35 Paine, MF, Shen, DD, Kunze, KL, et al. (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60, 1424.
36 Kupferschmidt, HH, Ha, HR, Ziegler, WH, et al. (1995) Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58, 2028.
37 Podszun, MC, Grebenstein, N, Hofmann, U, et al. (2013) High-dose supplementation with natural α-tocopherol does neither alter the pharmacodynamics of atorvastatin nor its phase I metabolism in guinea pigs. Toxicol Appl Pharmacol 266, 452458.
38 Wang, W & Higuchi, CM (1995) Induction of NAD(P)H: quinone reductase by vitamins A, E and C in Colo205 colon cancer cells. Cancer Lett 98, 6369.
39 Fisher, MB, Vandenbranden, M, Findlay, K, et al. (2000) Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10, 727739.
40 Van der Logt, EM, Roelofs, HM, van Lieshout, EM, et al. (2004) Effects of dietary anticarcinogens and nonsteroidal anti-inflammatory drugs on rat gastrointestinal UDP-glucuronosyltransferases. Anticancer Res 24, 843850.
41 Shitara, Y, Sato, H & Sugiyama, Y (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45, 689723.
42 König, J, Cui, Y, Nies, AT, et al. (2000) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278, G156G164.
43 Hsiang, B, Zhu, Y, Wang, Z, et al. (1999) A novel human hepatic organic anion transporting polypeptide (OATP2) identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274, 3716137168.
44 Hagenbuch, B & Meier, PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609, 118.
45 Traber, MG, Labut, EM, Leonard, SW, et al. (2011) α-Tocopherol injections in rats up-regulate hepatic ABC transporters, but not cytochrome P450 enzymes. Free Radic Biol Med 51, 20312040.
46 Farley, SM, Leonard, SW, Labut, EM, et al. (2012) Vitamin E decreases extra-hepatic menaquinone-4 concentrations in rats fed menadione or phylloquinone. Mol Nutr Food Res 56, 912922.
47 Bougle, D, Boutroy, MJ, Heng, J, et al. (1986) Plasma kinetics of parenteral tocopherol in premature infants. Dev Pharmacol Ther 9, 310316.
48 Guggenheim, MA, Ringel, SP, Silverman, A, et al. (1982) Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: diagnosis and treatment with α-tocopherol. J Pediatr 100, 5158.
49 Brion, LP, Bell, EF, Raghuveer, TS, et al. (2004) What is the appropriate intravenous dose of vitamin E for very-low-birth-weight infants? J Perinatol 24, 205207.
50 Sontag, TJ & Parker, RS (2002) Cytochrome P450 ω-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J Biol Chem 277, 2529025296.
51 Bardowell, SA, Duan, F, Manor, D, et al. (2012) Disruption of mouse cytochrome P450 4f14 (Cyp4f14) causes severe perturbations in vitamin E metabolism. J Biol Chem 287, 2607726086.
52 Lehmann, JM, McKee, DD, Watson, MA, et al. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102, 10161023.
53 Landes, N, Pfluger, P, Kluth, D, et al. (2003) Vitamin E activates gene expression via the pregnane X receptor. Biochem Pharmacol 65, 269273.
54 Podszun, MC, Grebenstein, N, Spruss, A, et al. (2014) Dietary α-tocopherol and atorvastatin reduce high-fat-induced lipid accumulation and down-regulate CD36 protein in the liver of guinea pigs. J Nutr Biochem 25, 573579.
55 Hundhausen, C, Frank, J, Rimbach, G, et al. (2006) Effect of vitamin E on cytochrome P450 mRNA levels in cultured hepatocytes (HepG2) and in rat liver. Cancer Genom Proteom 3, 183190.
56 Kluth, D, Landes, N, Pfluger, P, et al. (2005) Modulation of Cyp3a11 mRNA expression by α-tocopherol but not γ-tocotrienol in mice. Free Radic Biol Med 38, 507514.
57 Mustacich, DJ, Gohil, K, Bruno, RS, et al. (2009) α-Tocopherol modulates genes involved in hepatic xenobiotic pathways in mice. J Nutr Biochem 20, 469476.
58 Leonard, SW, Joss, JD, Mustacich, DJ, et al. (2007) Effects of vitamin E on cholesterol levels of hypercholesterolemic patients receiving statins. Am J Health Syst Pharm 64, 22572266.
59 Clarke, MW, Burnett, JR, Wu, JH, et al. (2009) Vitamin E supplementation and hepatic drug metabolism in humans. J Cardiovasc Pharmacol 54, 491496.
60 Manson, MM, Ball, H, Barrett, MC, et al. (1997) Mechanism of action of dietary chemoprotective agents in rat liver: induction of phase I and II drug metabolizing enzymes and aflatoxin B1 metabolism. Carcinogenesis 18, 17291738.
61 Van Haaften, RI, Evelo, CT, Penders, J, et al. (2001) Inhibition of human glutathione-S-transferase P1-1 by tocopherols and α-tocopherol derivatives. Biochim Biophys Acta 1548, 2328.
62 van Haaften, RI, Haenen, GR, Evelo, CT, et al. (2002) Tocotrienols inhibit human glutathione S-transferase P1-1. IUBMB Life 54, 8184.
63 Mustacich, DJ, Shields, J, Horton, RA, et al. (1998) Biliary secretion of α-tocopherol and the role of the mdr2 P-glycoprotein in rats and mice. Arch Biochem Biophys 350, 183192.
64 Food and Drug Administration (2008) Consumer Health Information. (accessed accessed July 2014).
65 Harper, M & Poole, A (2010) Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J Thromb Haemost 8, 454462.
66 Ali, M, Gudbranson, CG & McDonald, JWD (1980) Inhibition of human platelet cyclooxygenase by α-tocopherol. Prostaglandins Med 4, 7985.
67 Freedman, JE, Farhat, JH, Loscalzo, J, et al. (1996) α-Tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 94, 24342440.
68 Freedman, JE & Keaney, JF Jr (2001) Vitamin E inhibition of platelet aggregation is independent of antioxidant activity. J Nutr 131, 374S377S.
69 Liu, M, Wallmon, A, Olsson-Mortlock, C, et al. (2003) Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. Am J Clin Nutr 77, 700706.
70 Steiner, M (1983) Effect of α-tocopherol administration on platelet function in man. Thromb Haemost 49, 7377.
71 Vane, JR & Botting, RM (2003) The mechanism of action of aspirin. Thromb Res 110, 255258.
72 Liede, KE, Haukka, JK, Saxen, LM, et al. (1998) Increased tendency towards gingival bleeding caused by joint effect of α-tocopherol supplementation and acetylsalicylic acid. Ann Med 30, 542546.
73 Steiner, M, Glantz, M & Lekos, A (1995) Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 62, Suppl., 1381S1384S.
74 Suttie, JW (1980) Mechanism of action of vitamin K: synthesis of γ-carboxyglutamic acid. CRC Crit Rev Biochem 8, 191223.
75 Hirsh, J, Dalen, JE, Anderson, DR, et al. (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 108, Suppl., 231S246S.
76 Corrigan, J & Ulfers, L (1981) Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency. Am J Clin Nutr 34, 17011705.
77 Kim, JM & White, RH (1996) Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol 77, 545546.
78 Booth, SL, Golly, I, Sacheck, JM, et al. (2004) Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status. Am J Clin Nutr 80, 143148.
79 Widdershoven, J, Van Munster, P, De Abreu, R, et al. (1987) Four methods compared for measuring des-carboxy-prothrombin (PIVKA-II). Clin Chem 33, 20742078.
80 Edson, KZ, Prasad, B, Unadkat, JD, et al. (2013) Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry 52, 82768285.
81 Farley, SM, Leonard, SW, Taylor, AW, et al. (2013) ω-Hydroxylation of phylloquinone by CYP4F2 is not increased by α-tocopherol. Mol Nutr Food Res 57, 17851793.
82 Shiotani, A, Kamada, T & Haruma, K (2008) Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol 43, 581588.
83 Fisher, B, Redmond, C, Legault-Poisson, S, et al. (1990) Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8, 10051018.
84 Shou, J, Massarweh, S, Osborne, CK, et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96, 926935.
85 Chang, H, Huang, J, Wang, J, et al. (2002) Tamoxifen-induced increases in cytoplasmic free Ca2+ levels in human breast cancer cells. Breast Cancer Res Treat 71, 125131.
86 Peralta, EA, Viegas, ML, Louis, S, et al. (2006) Effect of vitamin E on tamoxifen-treated breast cancer cells. Surgery 140, 607615.
87 Peralta, EA, Brewer, AT, Louis, S, et al. (2009) Vitamin E increases biomarkers of estrogen stimulation when taken with tamoxifen. J Surg Res 153, 143147.
88 Baliga, R, Ueda, N, Walker, PD, et al. (1997) Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 29, 465477.
89 Blackhall, ML, Fassett, RG, Sharman, JE, et al. (2005) Effects of antioxidant supplementation on blood cyclosporin A and glomerular filtration rate in renal transplant recipients. Nephrol Dial Transplant 20, 19701975.
90 de Vries, AP, Oterdoom, LH, Gans, RO, et al. (2006) Supplementation with anti-oxidants vitamin C and E decreases cyclosporine A trough-levels in renal transplant recipients. Nephrol Dial Transplant 21, 231232.
91 Lake, KD, Aaronson, KD, Gorman, LE, et al. (2005) Effect of oral vitamin E and C therapy on calcineurin inhibitor levels in heart transplant recipients. J Heart Lung Transplant 24, 990994.
92 Barany, P, Stenvinkel, P, Ottosson-Seeberger, A, et al. (2001) Effect of 6 weeks of vitamin E administration on renal haemodynamic alterations following a single dose of neoral in healthy volunteers. Nephrol Dial Transplant 16, 580584.
93 Hebert, M (1997) Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 27, 201214.
94 Vacca, JP & Condra, JH (1997) Clinically effective HIV-1 protease inhibitors. Drug Discov Today 2, 261272.
95 Dressman, J, Kincer, J, Matveev, SV, et al. (2003) HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 111, 389397.
96 Munteanu, A, Zingg, JM, Ricciarelli, R, et al. (2005) CD36 overexpression in ritonavir-treated THP-1 cells is reversed by α-tocopherol. Free Radic Biol Med 38, 10471056.
97 Barella, L, Muller, PY, Schlachter, M, et al. (2004) Identification of hepatic molecular mechanisms of action of α-tocopherol using global gene expression profile analysis in rats. Biochim Biophys Acta 1689, 6674.
98 Gaedicke, S, Zhang, X, Schmelzer, C, et al. (2008) Vitamin E dependent microRNA regulation in rat liver. FEBS Lett 582, 35423546.
99 Meydani, SN, Meydani, M, Rall, L, et al. (1994) Assessment of the safety of high-dose, short-term supplementation with vitamin E in healthy older adults. Am J Clin Nutr 60, 704709.
100 Meydani, M, Lipman, R, Han, S, et al. (1998) The effect of long-term dietary supplementation with antioxidants. Ann N Y Acad Sci 854, 352360.
101 Milman, U, Blum, S, Shapira, C, et al. (2008) Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2–2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 28, 341347.
102 Vardi, M, Blum, S & Levy, AP (2012) Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Eur J Intern Med 23, 628632.
103 Blum, S, Vardi, M, Brown, JB, et al. (2010) Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2–2 genotype. Pharmacogenomics 11, 675684.
104 Scientific Committee on Food (SCF) (2003) Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin E.



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed